// App-Quantinova.ai

P5-06-02 : Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC)

Researchers

Presenter

  • Sibylle Loibl

Principal Investigators

  • Marc Buyse

  • Andr Robidoux

  • Luca Gianni

  • Andreas Schneeweiss

  • Pierfranco Conte

  • Martine Piccart

  • Herv Bonnefoi

  • Christian Jackisch

  • Valentina Nekljudova

  • Joseph Costantino

  • Pinuccia Valagussa

  • Colin Neate

  • Richard Gelber

  • Coralie Poncet

  • Pierre Squifflet

  • Everardo Saad

  • Dominik Heinzmann

  • Carsten Denkert

  • Charles E Geyer, Jr

  • Javier Cortes

  • Valentina Guarneri

  • Evandro de Azambuja

  • David Cameron

  • Gustavo Ismael

  • Gunter von Minckwitz

  • Norman Wolmark

  • Patricia Cortazar

Medical Centers

  • German Breast Group (GBG), Neu-Isenbug, Germany

  • HELIOS Klinikum Berlin-Buch, Berlin, Germany

  • International Drug Development Institute, Louvain-La-Neuve, Belgium

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • San Raffaele Scientific Institute, Milan, Italy

  • NCT Nationales Centrum fuer Tumorerkrankungen Heidelberg, Heidelberg, Germany

  • Department of Surgery, Oncology and Gastroenterology -DiSCOG, University of Padova, Padova, Italy

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

  • Institut Bergonié and Université de Bordeaux INSERM U916, Bordeaux, France

  • Sana Klinikum, Offenbach, Germany

  • NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA

  • Fondazione Michelangelo, Milan, Italy

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, and Frontier Science and Technology Research Foundation, Boston, MA

  • an Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium

  • Institut fur Pathologie, Philipps-Universitat Marburg und Universitatsklinikum Marburg, Marburg, Germany

  • Virginia Commonwealth University Medical Center, Richmond, VA

  • IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Department of Surgery, Oncology and Gastroenterology, University of Padua, Medical Oncology 2, Instituto Oncologico Veneto IRCCS, Padova, Italy

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

  • Edinburgh Cancer Research Center, University of Edinburgh, Edinburgh, United Kingdom

  • Fundação Amaral Carvalho, Jaú, Brazil

  • Genentech, Inc., South San Francisico, CA

Locations

  • Germany

  • Belgium

  • Canada

  • Italy

  • France

  • United States

  • Switzerland

  • Spain

  • United Kingdom

  • Brazil

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved